Overview
Orthofix Q3 net sales rose 5% yr/yr to $205.6 mln, beating analyst expectations
Adjusted EBITDA for Q3 increased 28.2% yr/yr, beating analyst estimates
Company narrowed full-year net sales guidance, raised low end of adjusted EBITDA guidance
Outlook
Orthofix narrows 2025 net sales guidance to $810 mln-$814 mln
Orthofix raises low end of 2025 adjusted EBITDA guidance to $84 mln-$86 mln
Orthofix expects positive free cash flow for 2025, excluding M6 restructuring charges
Result Drivers
SPINE FIXATION GROWTH - U.S. Spine Fixation net sales grew 8%, driven by 7D FLASH™ navigation technology
BONE GROWTH THERAPIES - Bone Growth Therapies net sales increased by 6% due to effective cross-selling and leveraging access points
ORTHOPEDICS LAUNCH - U.S. Orthopedics net sales grew 19%, aided by the launch of TrueLok™ Elevate
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Beat | $205.60 mln | $200 mln (5 Analysts) |
Q3 EPS | -$0.57 | ||
Q3 Adjusted EBITDA | Beat | $24.60 mln | $20.19 mln (5 Analysts) |
Q3 Gross Margin | 72.20% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Orthofix Medical Inc is $23.00, about 30.2% above its November 3 closing price of $16.06
Press Release: ID:nBw3gn6Hza
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)